Prothena Ord Share Price (0Y3M)

RA Capital’s largest new positions are Dyne Therapeutics, a clinical-stage biotech company that is innovating muscle-targeted therapeutics for genetic diseases, and Edgewise Therapeutics, a muscle disease biopharmaceuticals company. They rank 16th and 18th, respectively, in the U.S. portfolio.

They added during the rise here , the rise before the add was from the $5.85 low November to the $36 notice of adding April .

They have inside knowledge .

5.85 to 36 = 500 %

What a timely top up buy in Janux Therapeutics was $52.65 on 12/4/2024 it was up 10 times from 9th November 2023 when $5.85 a 5 year low , they increased position by 15 % last few weeks when price was around $36 1/4/2024.

36 to 52.65 = 46%

April 23, 2024

The biopharma specialist has made a flurry of major new purchases in recent weeks.

Biopharma hedge funds have been on a buying spree the past several weeks. Many of them reported in regulatory filings that they have initiated positions of at least 5 percent in individual stocks or boosted positions to well in excess of 5 percent of outstanding shares.

No firm, however, has been nearly as aggressive as RA Capital Management. In just the past four weeks, it has filed seven initial 13G or 13D documents indicating new investments of 5 percent or more. It also filed amended documents saying it has added to positions in at least four companies that are now holdings of 5 percent or more. Two of the new positions currently rank among the firm’s top-18 holdings, and three stocks in which RA Capital increased existing stakes were catapulted into the firm’s top eight.

This flurry of activity is unusual among life sciences and biopharma hedge funds, which rarely shuffle their portfolio’s largest positions from quarter to quarter. They are generally more of a buy-and-hold crowd, betting on firms they believe have the next drugs with the potential to receive FDA approval. Of course, given these fledgling companies’ small market caps, it does not take much capital to reach the 5 percent that triggers a 13D or 13G filing.

RA Capital is headed by founder Peter Kolchinsky and managing partner Rajeev Shah. As Institutional Investor previously reported, its hedge fund is up 14 percent for the year through March.

With the recent transactions, three stocks have moved onto the firm’s top-ten list.

Janux Therapeutics is the firm’s fourth-largest long, representing 5.72 percent of RA Capital’s U.S. common stock assets after the stake was boosted by more than 15 percent. The hedge fund firm now owns about 20 percent of the total shares outstanding. It is no stranger to Janux, as it was a major venture capital shareholder before the company went public in 2021. Janux is designing T cell immunotherapies that will kill tumors without impacting healthy tissue.

89bio is the seventh-largest long since RA Capital expanded its stake by nearly 25 percent. The hedge fund now has more than 15 percent of the clinical-stage biopharmaceuticals company, which develops therapies for liver and cardiometabolic diseases.

And Tyra Biosciences is the eighth-largest long after the firm recently lifted its stake by about 45 percent. RA Capital now owns more than 25 percent of the total shares. Tyra describes itself as a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in fibroblast growth factor receptor biology.

Redmile Group, LLC

Sold out of these on 31/12 /2022 & Jazz pharmaceuticals 30/9/23 .

They still have a large holding in Scancell ( SCLP ) 29% which they increased by 12% 20/12/23 from previous 17%

Bought the rest of yesterdays small part of order for slightly less $2.5

The lesser price paid just about covering today's dealing cost.

Set last night dealt at USA open , could of got for $2.45.... 30 mins later down... 6pm 3% down at $2.46